Variants in the APOE Gene Are Associated with Improved Outcome after Anti-VEGF Treatment for Neovascular AMD
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
PURPOSE: Anti-vascular endothelial growth factor (anti-VEGF) drugs have dramatically improved the treatment of neovascular AMD. In pivotal studies, almost 90% of patients maintain vision, with approximately 30% showing significant improvement. Despite these successes, 10% to 15% of patients continue to lose vision, even with treatment. It has been reported that variants in some AMD-associated genes influence treatment outcome. This study showed an association of treatment outcome with variants in the apolipoprotein E (APOE) gene. METHODS: One hundred ninety-two patients receiving anti-VEGF treatment for subfoveal choroidal neovascularization secondary to AMD were enrolled. Information on demographics, lesion characteristics, delay until treatment, visual acuity (VA), and number of treatments was collected, and variants of APOE were assessed in all patients at baseline. Best corrected logarithm of the minimum angle of resolution (logMAR) VA was recorded in all patients. RESULTS: The presence of the APOE ε4 allele was associated with improved treatment outcome at 3 (P = 0.02) and 12 (P = 0.06) months, compared with the presence of the ε2 allele, after adjustment for baseline acuity, treatment delay after first symptoms, age, and sex. Patients with an APOE ε4 allele had an odds ratio (OR) of 4.04 (95% confidence interval [CI], 1.11-14.70) for a 2-line gain in vision from baseline at 3 months (P = 0.03) and an OR of 2.54 (95% CI, 0.61-10.52; P = 0.20) at 12 months after treatment, based on multivariate analysis. CONCLUSIONS: In patients with neovascular AMD, the presence of the APOE ε4 allele conferred significantly better visual outcomes after anti-VEGF treatment than did the ε2 allele. These findings suggest a possible role for a personalized approach to treatment with anti-VEGF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
The Role of Oxidative Stress in the Pathogenesis of Age-Related Macular Degeneration
Beatty, S., Koh, H.-H., Phil, M., Henson, D., & Boulton, M. (2000) · Survey of Ophthalmology · doi:10.1016/s0039-6257(00)00140-5 · Cited by 2,051
Regillo, C. D., Brown, D. M., Abraham, P., Yue, H., Ianchulev, T., Schneider, S., & Shams, N. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.10.004 · Cited by 858
An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice
Ambati, J., Anand, A., Fernandez, S., Sakurai, E., Lynn, B. C., Kuziel, W. A., Rollins, B. J., & Ambati, B. K. (2003) · Nature Medicine · doi:10.1038/nm950 · Cited by 631
Association between C-reactive protein and age-related macular degeneration
Seddon, J. M. (2004) · JAMA · doi:10.1001/jama.291.6.704 · Cited by 376
Kaiser, P. K., Brown, D. M., Zhang, K., Hudson, H. L., Holz, F. G., Shapiro, H., Schneider, S., & Acharya, N. R. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.08.012 · Cited by 361
Anderson, D. H., Ozaki, S., Nealon, M., Neitz, J., Mullins, R. F., Hageman, G. S., & Johnson, L. V. (2001) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(00)00961-2 · Cited by 255
Self-citationLee, A. Y., Raya, A. K., Kymes, S. M., Shiels, A., & Brantley, M. A. (2009) · British Journal of Ophthalmology · doi:10.1136/bjo.2008.150995 · Cited by 134
Otani, A., Takagi, H., Oh, H., Koyama, S., Ogura, Y., Matumura, M., & Honda, Y. (2002) · Microvascular Research · doi:10.1006/mvre.2002.2407 · Cited by 128
Regulated expression of apolipoprotein E by human retinal pigment epithelial cells
Ishida, B. Y., Bailey, K. R., Duncan, K. G., Chalkley, R. J., Burlingame, A. L., Kane, J. P., & Schwartz, D. M. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m300306-jlr200 · Cited by 111
Apolipoprotein (APOE) gene is associated with progression of age-related macular degeneration (AMD)
Baird, P. N., Richardson, A. J., Robman, L. D., Dimitrov, P. N., Tikellis, G., McCarty, C. A., & Guymer, R. H. (2006) · Human Mutation · doi:10.1002/humu.20288 · Cited by 105
Self-citationBojanowski, C. M., Shen, D., Chew, E. Y., Ning, B., Csaky, K. G., Green, W. R., Chan, C., & Tuo, J. (2006) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20233 · Cited by 62
Feng, X., Xiao, J., Longville, B., Tan, A. X. J., Wu, X. N., Cooper, M. N., McAllister, I. L., Isaacs, T., Palmer, L. J., & Constable, I. J. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.03.011 · Cited by 54
Seitsonen, S. P., Järvelä, I. E., Meri, S., Tommila, P. V., Ranta, P. H., & Immonen, I. J. (2007) · European Journal of Ophthalmology · doi:10.1177/112067210701700612 · Cited by 48
Cited by
Age-related macular degeneration
Lim, L. S., Mitchell, P., Seddon, J. M., Holz, F. G., & Wong, T. Y. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60282-7 · Cited by 1,717
A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration
Schmidt-Erfurth, U., & Waldstein, S. M. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.07.007 · Cited by 390
“Numerous studies, including subgroup analyses of the major randomized prospective trials, have consistently reported a significant association between older age and poorer outcomes of anti-VEGF therapy for neovascular AMD (Boyer et al., 2007; Kaiser et al., 2007; Lim et al., 2012a; Wickremasinghe et al., 2011; Ying et…”
BackgroundRisk factors and biomarkers of age-related macular degeneration
Lambert, N. G., ElShelmani, H., Singh, M. K., Mansergh, F. C., Wride, M. A., Padilla, M., Keegan, D., Hogg, R. E., & Ambati, B. K. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.04.003 · Cited by 351
Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration
Finger, R. P., Wickremasinghe, S. S., Baird, P. N., & Guymer, R. H. (2014) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2013.03.009 · Cited by 144
Self-citationMcKibbin, M., Ali, M., Bansal, S., Baxter, P. D., West, K., Williams, G., Cassidy, F., & Inglehearn, C. F. (2012) · British Journal of Ophthalmology · doi:10.1136/bjo.2010.193680 · Cited by 100
Metadata
- Authors
- Wickremasinghe, S. S., Xie, J., Lim, J., Chauhan, D. S., Robman, L., Richardson, A. J., Hageman, G., Baird, P. N., & Guymer, R.
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2011-06-08
- Volume
- 52
- Issue
- 7
- Pages
- 4072
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W1977415091
- Cited by
- 58
- References
- 14
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.